Sweet Success: Unveiling the Power of Continuous Glucose Monitoring

1. There is a direct correlation between greater self-monitoring blood glucose (SMBG) frequency and lower A1C.

a) True
b) False

2. The first professional continuous glucose monitoring system (CGM) was approved in 1999.

a) True
b) False

3. Continuous glucose monitors measure the glucose in the interstitial fluid, not in the blood.

a) True
b) False

4. An appropriate candidate for a CGM would be:

a) Patients with high risk of hypoglycemia
b) Patients experiencing large variability of glucose levels (ex: low fasting and high A1C)
c) Patients that have not achieved their target A1C level
d) All of the Above

5. A CGM is comprised of a sensor, transmitter and receiver.

a) True
b) False

6. The following factors need to be considered when patients are prescribed a CGM:

a) Tylenol/acetaminophen may cause false highs if the patient is using a Dexcom or Guardian CGM
b) High doses of Vitamin C may cause false highs if the patient is using a Freestyle Libre
c) All of the Above

7. Time in range (TIR) refers to the amount of time the patient is achieving their individualized target blood sugar levels.

a) True
b) False

8. Standardized CGM metrics for clinical care include:

a) Achieving >70% TIR for most patients, >50% TIR in the elderly
b) Keeping time below range <4% in most patients, <1% in the elderly
c) Achieving <36% glycemic variability
d) All of the above

9. It is recommended to individualize target blood sugar levels for a patient on a CGM so they are less apt to experience alarm fatigue.

a) True
b) False